RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
RELMADA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.16+0.06 (+1.94%)
Close on Oct 19, 2026
- Market cap
- $355.11M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
94.0%
100M of 107M shares
Institutional holders
126
47 new, 23 sold out
Net institutional buying
26M
In Q2 2026
Insider trades, 12 months
10 buys · 0 sales
Net bought $4.03M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7,439,415 | 10.10% | 13G (passive) | Jan 30, 2026 |
| BlackRock, Inc. | 7,352,913 | 7.00% | 13G (passive) | Jun 30, 2026 |
| Squadron Master Fund LP | 7,350,000 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| VHCP Management III, LLC | 6,508,433 | 6.20% | 13G (passive) | Jun 2, 2026 |
| Commodore Capital LP | 5,505,527 | 5.10% | 13G (passive) | Apr 27, 2026 |
| Adage Capital Management, L.P. | 4,270,000 | 5.82% | 13G (passive) | Dec 31, 2025 |
| Simon Basseyn | 4,086,181 | 5.57% | 13G (passive) | Dec 31, 2025 |
| William Blank | 3,298,500 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Squadron Capital Management LLC | 2,050,000 | 6.20% | 13G (passive) | Apr 24, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RLMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 11,164,803 | 10.47% | $77.32M | New | 0.03% |
| BlackRock, Inc. | 7,426,780 | 6.96% | $51.39M | +6,137,230 | 0.00% |
| Squadron Capital Management LLC | 7,350,000 | 6.89% | $50.86M | −1,124,571 | 15.78% |
| VR Adviser, LLC | 6,844,305 | 6.42% | $47.36M | +2,000,925 | 1.44% |
| Spruce Street Capital LP | 6,391,328 | 5.99% | $44.23M | +129,214 | 8.68% |
| Adage Capital Partners Gp, L.L.C. | 4,763,158 | 4.47% | $32.96M | – | 0.05% |
| Vanguard Capital Management LLC | 4,460,210 | 4.18% | $30.86M | +1,383,640 | 0.00% |
| Jones Hill Capital LP | 3,655,075 | 3.43% | $25.29M | +3,312,323 | 5.38% |
| Orbimed Advisors LLC | 3,631,195 | 3.40% | $25.13M | −1,084,669 | 0.47% |
| State Street Corp | 2,517,550 | 2.36% | $17.42M | +2,160,510 | 0.00% |
| Geode Capital Management, LLC | 2,492,573 | 2.34% | $17.25M | +1,643,890 | 0.00% |
| Millennium Management LLC | 2,361,827 | 2.21% | $16.34M | −1,545,438 | 0.01% |
| Marshall Wace, Llp | 2,246,839 | 2.11% | $15.55M | −2,234,767 | 0.01% |
| Ikarian Capital, LLC | 2,148,359 | 2.01% | $14.87M | −540,000 | 1.60% |
| Driehaus Capital Management LLC | 2,132,053 | 2.00% | $14.75M | – | 0.09% |
| Ameriprise Financial Inc | 1,937,972 | 1.82% | $13.41M | +347,026 | 0.00% |
| Eventide Asset Management, LLC | 1,858,416 | 1.74% | $12.86M | +1,016,310 | 0.17% |
| Balyasny Asset Management L.P. | 1,520,688 | 1.43% | $10.52M | +1,268,231 | 0.01% |
| Stempoint Capital LP | 1,460,093 | 1.37% | $10.10M | +265,275 | 1.74% |
| Commodore Capital LP | 1,425,000 | 1.34% | $9.86M | +791,099 | 0.59% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 126 | 100M | 94.0% | 47 / 36 | 22 / 23 | 40M | 14M |
| Q1 2026 | 103 | 85M | 80.0% | 37 / 27 | 25 / 10 | 40M | 5M |
| Q4 2025 | 78 | 52M | 48.5% | 35 / 23 | 7 / 1 | 44M | 0M |
| Q3 2025 | 44 | 8M | 7.3% | 2 / 13 | 12 / 8 | 3M | 0M |
| Q2 2025 | 50 | 5M | 5.0% | 13 / 6 | 13 / 7 | 2M | 3M |
| Q1 2025 | 44 | 6M | 5.8% | 8 / 4 | 14 / 12 | 0M | 3M |
| Q4 2024 | 48 | 8M | 7.9% | 7 / 11 | 20 / 28 | 1M | 5M |
| Q3 2024 | 69 | 13M | 11.9% | 7 / 11 | 25 / 15 | 2M | 2M |
| Q2 2024 | 79 | 14M | 13.0% | 6 / 15 | 31 / 19 | 1M | 2M |
| Q1 2024 | 93 | 15M | 13.8% | 19 / 22 | 25 / 9 | 3M | 2M |
| Q4 2023 | 83 | 14M | 12.9% | 14 / 27 | 19 / 16 | 3M | 4M |
| Q3 2023 | 88 | 15M | 14.1% | 7 / 11 | 40 / 14 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RLMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,169,804 | 2.97% | $21.94M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,087,837 | 1.96% | $14.45M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,204,852 | 1.13% | $8.34M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,035,434 | 0.97% | $5.50M | 0.02% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,016,310 | 0.95% | $7.03M | 0.39% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 865,607 | 0.81% | $5.99M | 0.04% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 788,718 | 0.74% | $4.19M | 0.36% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 655,062 | 0.61% | $4.53M | 1.06% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 438,901 | 0.41% | $3.04M | 6.84% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 379,189 | 0.36% | $2.73M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 317,798 | 0.30% | $2.20M | 0.14% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 229,629 | 0.22% | $1.22M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 176,772 | 0.17% | $1.22M | 0.02% | Jun 30, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 163,750 | 0.15% | $1.13M | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 144,336 | 0.14% | $1.04M | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sergio Traversa | Chief Executive Officer, Director | 1,500,000 | 1.41% | Sep 11, 2026 |
| Paul Edward Kelly | COO, Director | 502,295 | 0.47% | Dec 16, 2025 |
| Maged Shenouda | Chief Financial Officer | 1,000,000 | 0.94% | Sep 11, 2026 |
| Chuck Ence | CA and CO | 403,931 | 0.38% | Dec 16, 2025 |
| Charles J. Casamento | Director | 10,000 | 0.01% | Dec 16, 2025 |
| John Glasspool | Director | 75,000 | 0.07% | Dec 16, 2025 |
| Fabiana Fedeli | Director | – | – | Dec 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sergio Traversa Chief Executive Officer, Director | Sep 10, 2026 | Buy | +100,000 | $4.10 | $410.00K | 1,500,000 |
| Maged Shenouda Chief Financial Officer | Sep 10, 2026 | Buy | +79,800 | $4.25 | $339.15K | 1,000,000 |
| Sergio Traversa Chief Executive Officer, Director | Sep 9, 2026 | Buy | +100,000 | $4.18 | $418.00K | 1,400,000 |
| Maged Shenouda Chief Financial Officer | Sep 9, 2026 | Buy | +120,200 | $4.20 | $504.84K | 920,200 |
| Maged Shenouda Chief Financial Officer | Dec 15, 2025 | Buy | +11,665 | $4.12 | $48.06K | 800,000 |
| Sergio Traversa Chief Executive Officer, Director | Dec 15, 2025 | Buy | +27,500 | $4.12 | $113.30K | 1,300,000 |
| Sergio Traversa Chief Executive Officer, Director | Nov 5, 2025 | Buy | +272,500 | $2.20 | $599.50K | 1,272,500 |
| Chuck Ence CAO and COO | Nov 5, 2025 | Buy | +136,000 | $2.20 | $299.20K | 403,931 |
| Maged Shenouda Chief Financial Officer | Nov 5, 2025 | Buy | +500,000 | $2.20 | $1.10M | 788,335 |
| Paul Edward Kelly Chief Operating Officer, Director | Nov 5, 2025 | Buy | +90,000 | $2.20 | $198.00K | 502,295 |
| Sergio Traversa Chief Executive Officer, Director | Aug 28, 2025 | Buy | +55,976 | $0.74 | $41.42K | 1,000,000 |
| Sergio Traversa Chief Executive Officer, Director | Aug 27, 2025 | Buy | +129,455 | $0.67 | $86.73K | 944,024 |
| Sergio Traversa Chief Executive Officer, Director | Aug 26, 2025 | Buy | +80,545 | $0.62 | $49.94K | 814,569 |
| Sergio Traversa Chief Executive Officer, Director | May 20, 2025 | Buy | +147,686 | $0.56 | $82.70K | 734,024 |
| Maged Shenouda Chief Financial Officer | May 20, 2025 | Buy | +60,000 | $0.52 | $31.20K | 288,335 |
| Sergio Traversa Chief Executive Officer, Director | May 19, 2025 | Buy | +30,000 | $0.50 | $15.00K | 586,338 |
| Maged Shenouda Chief Financial Officer | May 19, 2025 | Buy | +90,000 | $0.49 | $44.10K | 228,335 |
| Sergio Traversa Chief Executive Officer, Director | May 16, 2025 | Buy | +172,314 | $0.45 | $77.54K | 556,338 |
| Paul Edward Kelly Chief Operating Officer, Director | May 16, 2025 | Buy | +200,000 | $0.43 | $86.00K | 412,295 |
| Maged Shenouda Chief Financial Officer | May 16, 2025 | Buy | +50,000 | $0.44 | $22.00K | 138,335 |
| Chuck Ence CA and CO | May 16, 2025 | Buy | +228,961 | $0.45 | $103.03K | 267,931 |
| Charles J. Casamento Director | Oct 22, 2024 | Gift | −13,000 | – | – | 0 |
| Sergio Traversa Chief Executive Officer, Director | Sep 11, 2024 | Buy | +51,407 | $2.99 | $153.71K | 384,024 |
| Maged Shenouda Chief Financial Officer | Sep 11, 2024 | Buy | +24,120 | $2.95 | $71.15K | 88,335 |
| Sergio Traversa Chief Executive Officer, Director | Sep 10, 2024 | Buy | +33,014 | $2.75 | $90.79K | 332,617 |
| Maged Shenouda Chief Financial Officer | Sep 10, 2024 | Buy | +21,118 | $2.73 | $57.65K | 64,215 |
| Sergio Traversa Chief Executive Officer, Director | Sep 9, 2024 | Buy | +55,579 | $2.71 | $150.62K | 299,603 |
| Maged Shenouda Chief Financial Officer | Sep 9, 2024 | Buy | +8,194 | $2.55 | $20.89K | 43,097 |
| Charles J. Casamento Director | Sep 9, 2024 | Buy | +13,000 | $2.56 | $33.28K | 13,000 |
| Paul Edward Kelly Director | Sep 9, 2024 | Buy | +25,000 | $2.59 | $64.75K | 212,295 |
| Maged Shenouda Chief Financial Officer | Jan 31, 2024 | Buy | +6,875 | $4.06 | $27.91K | 34,903 |
| Chuck Ence CA and CO | Jan 31, 2024 | Buy | +13,670 | $4.05 | $55.36K | 38,970 |
| Sergio Traversa Chief Executive Officer, Director | Jan 31, 2024 | Buy | +27,460 | $4.00 | $109.84K | 244,024 |
| Maged Shenouda Chief Financial Officer | Jan 30, 2024 | Buy | +15,000 | $3.89 | $58.35K | 28,028 |
| Chuck Ence CA and CO | Jan 30, 2024 | Buy | +14,500 | $3.87 | $56.12K | 25,300 |
| Sergio Traversa Chief Executive Officer, Director | Jan 30, 2024 | Buy | +40,999 | $3.90 | $159.90K | 216,564 |
| Maged Shenouda Chief Financial Officer | Jan 29, 2024 | Buy | +10,800 | $3.65 | $39.42K | 13,028 |
| Chuck Ence CA and CO | Jan 29, 2024 | Buy | +10,800 | $3.65 | $39.42K | 10,800 |
| Sergio Traversa Chief Executive Officer, Director | Jan 29, 2024 | Buy | +31,541 | $3.71 | $117.02K | 175,565 |
| Cedric O'Gorman Chief Medical Officer | May 23, 2023 | Buy | +10,000 | $3.18 | $31.80K | 10,121 |
| Sergio Traversa Chief Executive Officer, Director | Dec 8, 2022 | Buy | +55,250 | $2.10 | $116.03K | 144,024 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Sale | −839 | $18.48 | $15.50K | 101,690 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Sale | −8,848 | $18.45 | $163.25K | 92,842 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Sale | −4,068 | $18.32 | $74.53K | 88,774 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Option exercise | +13,755 | $16.00 | $220.08K | 102,529 |
| Sergio Traversa Chief Executive Officer, Director | Jun 30, 2022 | Option exercise | +16,012 | $16.00 | $256.19K | 104,786 |
| Sergio Traversa Chief Executive Officer, Director | Jun 30, 2022 | Sale | −5,314 | $19.37 | $102.93K | 99,472 |
| Sergio Traversa Chief Executive Officer, Director | Jun 30, 2022 | Sale | −10,698 | $19.01 | $203.37K | 88,774 |
| Paul Edward Kelly Director | Apr 4, 2022 | Option exercise | +10,000 | $3.24 | $32.40K | 197,295 |
| Paul Edward Kelly Director | Apr 4, 2022 | Sale(10b5-1 plan) | −10,000 | $30.04 | $300.40K | 187,295 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 13,200 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 16,500 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 9,900 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 6,600 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 3,300 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 0 |
| Charles J. Casamento Director | Apr 1, 2022 | Option exercise | +19,800 | $3.24 | $64.15K | 19,800 |
| Paul Edward Kelly Director | Jan 3, 2022 | Option exercise | −20,000 | $3.24 | $64.80K | 187,295 |
| Charles J. Casamento Director | Dec 3, 2021 | Gift | −10,000 | – | – | 0 |
| Charles J. Casamento Director | Dec 3, 2021 | Gift | +10,000 | – | – | 10,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cedric O'Gorman Officer | Feb 20, 2024 | 74,999 | $442.49K | Feb 20, 2024 | STOCK OPTION EXERCISE |